Komori
Other Disclosures4935LIBERTA CO.,LTD.Materials and Chemicals

Notice of the addition of two serums to the new skincare brand “MEDiLiA” lineup

2 individually packaged serums, P-DRN Shot and Azela Shot, will be added to the new MEDiLiA skincare brand. Following their early release at Loft and @cosme, they will be rolled out through Qoo10 and variety stores nationwide.

Worth reading
62In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
2
2 serums
Wording
Definitive
How definitive the wording is.

Announced details

MEDiLiA (Medilia)P-DRN ShotAzela Shot
Applicable field (uses covered by this announcement)

Skincare, serums, dryness-related skin irritation, sensitive or unstable skin, loss of firmness and elasticity, and anti-aging care

Launch datePlanned early release at Loft and @cosme on 2 November 2026 (Monday), planned Mega Debut on Qoo10 on 10 November 2026 (Tuesday), and planned release from 16 November 2026 (Monday) at variety stores nationwide, select drugstores, the official online store, and e-commerce marketplaces
Relationship between the counterparty and the company
LIBERTA CO.,LTD.4935
Relationship with the Company

The company uses these parties as sales destinations and sales channels for its products. No capital or personnel relationship is stated.

CounterpartyLOFT CO., LTD.@cosmeQoo10

Not stated.

Offering price

P-DRN Shot: ¥2,970 including tax (28 sachets) and ¥990 including tax (7 sachets) / Azela Shot: ¥2,970 including tax (28 sachets) and ¥990 including tax (7 sachets)

The company does not address Contract Value / Impact on Business Performance.

Source (materials cited by the company)

Research by the raw material manufacturer (as of September 2026) / Company research

Announced details
ItemDetails
Names of Products / Services CoveredMEDiLiA (Medilia), P-DRN Shot, Azela Shot
CounterpartyLOFT CO., LTD., @cosme, Qoo10
Counterparty overviewNot stated.
Relationship with the CompanyThe company uses these parties as sales destinations and sales channels for its products. No capital or personnel relationship is stated.
Offering priceP-DRN Shot: ¥2,970 including tax (28 sachets) and ¥990 including tax (7 sachets) / Azela Shot: ¥2,970 including tax (28 sachets) and ¥990 including tax (7 sachets)
Launch datePlanned early release at Loft and @cosme on 2 November 2026 (Monday), planned Mega Debut on Qoo10 on 10 November 2026 (Tuesday), and planned release from 16 November 2026 (Monday) at variety stores nationwide, select drugstores, the official online store, and e-commerce marketplaces
Applicable areaSkincare, serums, dryness-related skin irritation, sensitive or unstable skin, loss of firmness and elasticity, and anti-aging care
SourceResearch by the raw material manufacturer (as of September 2026) / Company research
Items this document does not state (10)
Contract ValueContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To address concerns such as skin problems during seasonal changes, dryness-related irritation, and loss of firmness.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the addition of two serums to the new skincare brand “MEDiLiA” lineup | LIBERTA CO.,LTD. (4935) timely disclosure | Komori